Axion’s multiwell MEA platform rapidly evaluates the cardiac safety risk of compounds using stem cell-derived cardiomyocytes. Electrical parameters such as repolarization timing and spontaneous action potential rate are interdependent, complicating the interpretation of drug effects. Experimentally controlling electrical activity through pacing removes this interdependence, increases the accuracy of the measured endpoints, and improves the information content of the assay.
Pacing with iCell Cardiomyocytes
